Artios Pharma Ltd.
- Country
- 🇬🇧United Kingdom
- Ownership
- Holding
- Established
- 2016-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.artiospharma.com
Clinical Trials
5
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (4 trials with phase data)• Click on a phase to view related trials
Study of ART6043 in Advanced/Metastatic Solid Tumors Patients
- Conditions
- Metastatic Solid TumorAdvanced Solid Tumor
- Interventions
- First Posted Date
- 2023-06-12
- Last Posted Date
- 2025-10-15
- Lead Sponsor
- Artios Pharma Ltd
- Target Recruit Count
- 220
- Registration Number
- NCT05898399
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center (MSKCC), New York, New York, United States
🇺🇸South Texas Accelerated Research Therapeutics (START) - Midwest, Grand Rapids, Michigan, United States
🇺🇸Stephenson Cancer Center - Oncology, Oklahoma City, Oklahoma, United States
Study of ART0380 in Patients With Biologically Selected Solid Tumors
- Conditions
- Metastatic CancerAdvanced Solid TumorRecurrent Endometrial Cancer
- Interventions
- First Posted Date
- 2023-04-04
- Last Posted Date
- 2025-06-13
- Lead Sponsor
- Artios Pharma Ltd
- Target Recruit Count
- 36
- Registration Number
- NCT05798611
- Locations
- 🇺🇸
University of California Los Angeles (UCLA), Los Angeles, California, United States
🇺🇸The University of Chicago, Chicago, Illinois, United States
🇺🇸Dana Farber Cancer Center, Boston, Massachusetts, United States
A Study of ART4215 for the Treatment of Advanced or Metastatic Solid Tumors
- Conditions
- Advanced CancerBreast CancerMetastatic Cancer
- Interventions
- First Posted Date
- 2021-08-05
- Last Posted Date
- 2025-04-18
- Lead Sponsor
- Artios Pharma Ltd
- Target Recruit Count
- 390
- Registration Number
- NCT04991480
- Locations
- 🇺🇸
Yale School of Medicine, New Haven, Connecticut, United States
🇺🇸Florida Cancer Specialists, Orlando, Florida, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
Tissue Collection for Correlation Between ATM Alterations by Next-Generation Sequencing and ATM Loss-of-Protein
- Conditions
- Solid Tumor, Unspecified, Adult
- First Posted Date
- 2021-07-26
- Last Posted Date
- 2022-08-01
- Lead Sponsor
- Artios Pharma Ltd
- Target Recruit Count
- 229
- Registration Number
- NCT04976803
- Locations
- 🇺🇸
Oklahoma University, Oklahoma City, Oklahoma, United States
🇺🇸Tennessee Oncology, Nashville, Tennessee, United States
🇬🇧Sarah Cannon Research UK, London, United Kingdom
A clinical study to assess the safety and efficacy of oral ART0380 as a single agent or in combination in solid tumors
- Conditions
- Advanced or Metastatic Solid Tumours
- Interventions
- First Posted Date
- 2020-12-08
- Last Posted Date
- 2025-10-14
- Lead Sponsor
- Artios Pharma Limited
- Target Recruit Count
- 502
- Registration Number
- 2024-511534-12-00
- Locations
- 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸Mayo Clinic (Arizona), Scottsdale, Arizona, United States
🇺🇸University of Arkansas - Winthrop P. Rockefeller Cancer Institute, Little Rock, Arkansas, United States